HomeFilePharmacology

Pharmacology

View Category

Pharmacology

ACC 2022 | VALOR-HCM: Mavacamten in Adults with Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy

Roughly 50% of hypertrophic cardiomyopathies (HCM) are obstructive, and of this percentage, most of symptoms can be...
solaci -
Learn More
Pharmacology

ACC 2022 – POISE-3: Tranexamic Acid, Bleeding and Cardiovascular Events in Non-Cardiac Surgeries

Tranexamic Acid is an antifibrinolytic which has been shown to reduce bleeding in orthopedic patients and cardiac...
solaci -
Learn More
Acute coronary syndromes

REVERSE-IT | Bentracimab: Progress on the Antidote for Ticagrelor in Emergency Scenarios

Optimizing an antiplatelet therapy after an acute coronary syndrome (ACS) aims at reducing the major adverse cardiac...
solaci -
Learn More
Acute coronary syndromes

Ticagrelor Monotherapy after 3 Months: Is the Current Strategy Worth Changing?

Dual antiplatelet therapy (DAPT) after PCI with DES has shown noticeable reduction of thrombotic events, especially in...
solaci -
Learn More
Acute coronary syndromes

Abbreviated DAPT in ACS: The End of Clopidogrel Monotherapy?

Compared with patients with chronic coronary syndromes, patients with acute coronary syndromes (ACS) are more likely to...
solaci -
Learn More
Acute coronary syndromes

Acute Coronary Syndrome: What Is Safer, Antiaggregant Monotherapy or De-Escalation?

For several years it has been shown that 12-month dual antiplatelet therapy (DAPT) is mandatory for patients...
solaci -
Learn More
Acute coronary syndromes

Cangrelor: Additional Research Findings Not Translating into Clinical Practice

The potent and fast endovenous platelet inhibition provided by Cangrelor reduces ischemic events early in the course...
solaci -
Learn More
Antiplatelet

Clnical Practice Dissociated from Study Outcomes: Bad News for Our Patients?

Differences in patient characteristics, changes in treatment algorithms, and advances in device technology, together or separately, might...
solaci -
Learn More